Recipharm Expands US Sterile Fill and Finish Capabilities
Recipharm announced a multi-million-dollar investment in its US operations, strengthening its ability to support pharma and biotech companies with advanced sterile fill and finish services.
Fill and Finish
Adragos Pharma Completes Acquisition of Sanofi’s Sterile Fill-Finish Site in France
Adragos Pharma has acquired Sanofi’s Maisons-Alfort sterile fill-finish site in France, expanding its European manufacturing network and prefilled syringe capabilities.
Sharp Sterile Manufacturing Increases Capacity with $28 Million Investment
Sharp Sterile Manufacturing announced a $28 million expansion of its Lee, Massachusetts site to boost pharmaceutical production capacity and create high-skilled life sciences jobs.
Aenova Expands Fill & Finish Capacities at its Latina site
Aenova will install an additional filling and manufacturing line at the Latina, Italy, site. This expansion is an important step to meet the increasing global demand for the production of biologics.
Pace Life Sciences Expands Sterile Filling Capabilities
Pace Life Sciences, a US-based contract research, development, and manufacturing organization (CRDMO), is remodeling and expanding its Salem, NH site for aseptic fill-finish processing.
Curia Announces Expansions to Global Network of Sterile Fill-Finish Sites
Curia, a CDMO, recently shared expansion plans for facilities in Glasgow, UK, and Albuquerque, NM, US.
Quotient Sciences Bolsters Sterile Fill/Finish Capacity
Quotient Sciences, a drug development and manufacturing accelerator, has invested significantly in expanding its sterile fill/finish capabilities at its Alnwick, UK facility. This expansion aims to meet the rising demand in the industry for comprehensive drug development programs by enhancing the capacity of the Annex 1-compliant facility.
Siegfried Demonstrates Biologics Expertise in Hameln
The Fill & Finish of biologic drugs is expensive and poses special technological challenges for CDMOs. At the German site in Hameln, Siegfried has successfully proven these capabilities over the past two years by producing Covid-19 vaccines and a significant number of clinical batches for several biological companies. By investing in its competencies, capacities and flexibility, the company intends to further expand this demanding but promising business area.
Lonza Builds Swiss Fill & Finish Facility
Swiss CDMO Lonza plans to build a large-scale commercial fill & finish facility in Stein. The new facility, to be located on the same campus as Lonza’s existing clinical drug product capabilities, will cost roughly 500 million Swiss francs and should be completed in 2026.
